Accès gratuit
Numéro
Med Sci (Paris)
Volume 27, Numéro 3, Mars 2011
Page(s) 269 - 274
Section M/S revues
DOI https://doi.org/10.1051/medsci/2011273269
Publié en ligne 30 mars 2011
  1. LeeRH, PulinAA, SeoMJ, et al. Intravenous hMSCs improve myocardial infarction in mice because cells embolized in lung are activated to secrete the anti-inflammatory protein TSG-6. Cell Stem Cell 2009 ; 5 : 54-63. [CrossRef] [PubMed]
  2. Le BlancK, FrassoniF, BallL, et al. Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study. Lancet 2008 ; 371 : 1579-1586. [CrossRef] [PubMed]
  3. von BoninM, StolzelF, GoedeckeA, et al. Treatment of refractory acute GVHD with third-party MSC expanded in platelet lysate-containing medium. Bone Marrow Transplant 2009 ; 43 : 245-251. [CrossRef] [PubMed]
  4. ParekkadanB, MilwidJM. Mesenchymal stem cells as therapeutics. Annu Rev Biomed Eng 2010 ; 12 : 87-117. [CrossRef] [PubMed]
  5. SunL, WangD, LiangJ, et al. Umbilical cord mesenchymal stem cell transplantation in severe and refractory systemic lupus erythematosus. Arthritis Rheum 2010 ; 62 : 2467-2475. [CrossRef] [PubMed]
  6. BenvenutoF, FerrariS, GerdoniE, et al. Human mesenchymal stem cells promote survival of T cells in a quiescent state. stem cells 2007 ; 25 : 1753-1760. [CrossRef] [PubMed]
  7. UccelliA, MorettaL, PistoiaV. Mesenchymal stem cells in health and disease. Nat Rev Immunol 2008 ; 8 : 726-736. [CrossRef] [PubMed]
  8. LiottaF, AngeliR, CosmiL, et al. Toll-like receptors 3 and 4 are expressed by human bone marrow-derived mesenchymal stem cells and can inhibit their T-cell modulatory activity by impairing Notch signaling. stem cells 2008 ; 26 : 279-289. [CrossRef] [PubMed]
  9. SelmaniZ, NajiA, ZidiI, et al. Human leukocyte antigen-G5 secretion by human mesenchymal stem cells is required to suppress T lymphocyte and natural killer function and to induce CD4+CD25highFOXP3+ regulatory T cells. stem cells 2008 ; 26 : 212-222. [CrossRef] [PubMed]
  10. GhannamS, PeneJ, Torcy-MoquetG, et al. Mesenchymal stem cells inhibit human Th17 cell differentiation and function and induce a T regulatory cell phenotype. Immunol 2010 ; 185 : 302-312. [CrossRef]
  11. KramperaM, CosmiL, AngeliR, et al. Role for interferon-gamma in the immunomodulatory activity of human bone marrow mesenchymal stem cells. Stem Cells 2006 ; 24 : 386-398. [CrossRef] [PubMed]
  12. Maby-El HajjamiH, Ame-ThomasP, PangaultC, et al. Functional alteration of the lymphoma stromal cell niche by the cytokine context: role of indoleamine-2, 3 dioxygenase. Cancer Res 2009 ; 69 : 3228-3237. [CrossRef] [PubMed]
  13. TraggiaiE, VolpiS, SchenaF, et al. Bone marrow-derived mesenchymal stem cells induce both polyclonal expansion and differentiation of B cells isolated from healthy donors and systemic lupus erythematosus patients. Stem Cells 2008 ; 26 : 562-569. [CrossRef] [PubMed]
  14. RafeiM, HsiehJ, FortierS, et al. Mesenchymal stromal cell-derived CCL2 suppresses plasma cell immunoglobulin production via STAT3 inactivation and PAX5 induction. Blood 2008 ; 112 : 4991-4998. [CrossRef] [PubMed]
  15. NautaAJ, KruisselbrinkAB, LurvinkE, et al. Mesenchymal stem cells inhibit generation and function of both CD34+-derived and monocyte-derived dendritic cells. Immunol 2006 ; 177 : 2080-2087.
  16. DjouadF, CharbonnierLM, BouffiC, et al. Mesenchymal stem cells inhibit the differentiation of dendritic cells through an interleukin-6-dependent mechanism. stem cells 2007 ; 25 : 2025-2032. [CrossRef] [PubMed]
  17. SpaggiariGM, AbdelrazikH, BecchettiF, MorettaL. MSCs inhibit monocyte-derived DC maturation and function by selectively interfering with the generation of immature DCs: central role of MSC-derived prostaglandin E2. Blood 2009 ; 113 : 6576-6583. [CrossRef] [PubMed]
  18. SpaggiariGM, CapobiancoA, AbdelrazikH, et al. Mesenchymal stem cells inhibit natural killer-cell proliferation, cytotoxicity, and cytokine production: role of indoleamine 2, 3-dioxygenase and prostaglandin E2. Blood 2008 ; 111 : 1327-1333. [CrossRef] [PubMed]
  19. SpaggiariGM, CapobiancoA, BecchettiS, et al. Mesenchymal stem cell-natural killer cell interactions: evidence that activated NK cells are capable of killing MSCs, whereas MSCs can inhibit IL-2-induced NK-cell proliferation. Blood 2006 ; 107 : 1484-1490. [CrossRef] [PubMed]
  20. MartinetL, Fleury-CappellessoS, GadelorgeM, et al. A regulatory cross-talk between Vgamma9Vdelta2 T lymphocytes and mesenchymal stem cells. Eur J Immunol 2009 ; 39 : 752-762. [CrossRef] [PubMed]
  21. OrtizLA, DutreilM, FattmanC, et al. Interleukin 1 receptor antagonist mediates the antiinflammatory and antifibrotic effect of mesenchymal stem cells during lung injury. Proc Natl Acad Sci USA 2007 ; 104 : 11002-11007. [CrossRef]
  22. KimJ, HemattiP. Mesenchymal stem cell-educated macrophages: a novel type of alternatively activated macrophages. Exp Hematol 2009 ; 37 : 1445-1453. [CrossRef] [PubMed]
  23. NemethK, LeelahavanichkulA, YuenPS, et al. Bone marrow stromal cells attenuate sepsis via prostaglandin E(2)-dependent reprogramming of host macrophages to increase their interleukin-10 production. Nat Med 2009 ; 15 : 42-49. [CrossRef] [PubMed]
  24. RaffaghelloL, BianchiG, BertolottoM, et al. Human mesenchymal stem cells inhibit neutrophil apoptosis: a model for neutrophil preservation in the bone marrow niche. Stem Cells 2008 ; 26 : 151-162. [CrossRef] [PubMed]
  25. PolchertD, SobinskyJ, DouglasG, et al. IFN-gamma activation of mesenchymal stem cells for treatment and prevention of graft versus host disease. Eur J Immunol 2008 ; 38 : 1745-1755. [CrossRef] [PubMed]
  26. NemethK, Keane-MyersA, BrownJM, et al. Bone marrow stromal cells use TGF-beta to suppress allergic responses in a mouse model of ragweed-induced asthma. Proc Natl Acad Sci USA 2010 ; 107 : 5652-5657. [CrossRef]
  27. OpitzCA, LitzenburgerUM, LutzC, et al. Toll-like receptor engagement enhances the immunosuppressive properties of human bone marrow-derived mesenchymal stem cells by inducing indoleamine-2, 3-dioxygenase-1 via interferon-beta and protein kinase R. stem cells 2009 ; 27 : 909-919. [CrossRef] [PubMed]
  28. Romieu-MourezR, FrancoisM, BoivinMN, et al. Cytokine modulation of TLR expression and activation in mesenchymal stromal cells leads to a proinflammatory phenotype. Immunol 2009 ; 182 : 7963-7973. [CrossRef]
  29. GonzalezMA, Gonzalez-ReyE, RicoL, et al. Treatment of experimental arthritis by inducing immune tolerance with human adipose-derived mesenchymal stem cells. Arthritis Rheum 2009 ; 60 : 1006-1019. [CrossRef] [PubMed]
  30. JonesS, HorwoodN, CopeA, DazziF. The antiproliferative effect of mesenchymal stem cells is a fundamental property shared by all stromal cells. Immunol 2007 ; 179 : 2824-2831.
  31. FrancoisM, Romieu-MourezR, Stock-MartineauS, et al. Mesenchymal stromal cells cross-present soluble exogenous antigens as part of their antigen-presenting cell properties. Blood 2009 ; 114 : 2632-2638. [PubMed]
  32. NautaAJ, WesterhuisG, KruisselbrinkAB, et al. Donor-derived mesenchymal stem cells are immunogenic in an allogeneic host and stimulate donor graft rejection in a nonmyeloablative setting. Blood 2006 ; 108 : 2114-2120. [CrossRef] [PubMed]
  33. TokoyodaK, HauserAE, NakayamaT, RadbruchA. Organization of immunological memory by bone marrow stroma. Nat Rev Immunol 2010 ; 10 : 193-200. [CrossRef] [PubMed]
  34. MuellerSN, GermainRN. Stromal cell contributions to the homeostasis and functionality of the immune system. Nat Rev Immunol 2009 ; 9 : 618-629. [PubMed]
  35. PedutoL, DulauroyS, LochnerM, et al. Inflammation recapitulates the ontogeny of lymphoid stromal cells. Immunol 2009 ; 182 : 5789-5799. [CrossRef]
  36. CoppeJP, DesprezPY, KrtolicaA, CampisiJ. The senescence-associated secretory phenotype: the dark side of tumor suppression. Annu Rev Pathol 2010 ; 5 : 99-118. [CrossRef] [PubMed]
  37. CharbordP, CasteillaL. La biologie des cellules souches mésenchymateuses d’origine humaine. Med Sci (Paris) 2011 ; 27 : 261-268. [CrossRef] [EDP Sciences] [PubMed]
  38. LazennecG. Les cellules souches mésenchymateuses : armes ou dangers pour le traitement des cancers ?. Med Sci (Paris) 2011 ; 27 : 285-288. [CrossRef] [EDP Sciences] [PubMed]

Les statistiques affichées correspondent au cumul d'une part des vues des résumés de l'article et d'autre part des vues et téléchargements de l'article plein-texte (PDF, Full-HTML, ePub... selon les formats disponibles) sur la platefome Vision4Press.

Les statistiques sont disponibles avec un délai de 48 à 96 heures et sont mises à jour quotidiennement en semaine.

Le chargement des statistiques peut être long.